Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma
- Chin Med J (Engl). 2012 Jun;125(12):2231-4.
- 1. Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Sporadic malignant pheochromocytoma, a rare disease with poor prognosis, is always difficult to treat due in part to lack of effective agents. We presented three patients with advanced malignant pheochromocytoma treated by sunitinib, which indicates that sunitinib is an effective agent for this malignancy.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: c-Met/HGFRResearch Areas: Cancer
-
Research Areas: Cancer